Low dose endoluminal photodynamic therapy improves murine T cell-mediated colitis.

TitreLow dose endoluminal photodynamic therapy improves murine T cell-mediated colitis.
Publication TypeJournal Article
Year of Publication2011
AuthorsFavre, L, Borle, F, Velin, D, Bachmann, D, Bouzourene, H, Wagnieres, G, van den Bergh, H, Ballabeni, P, Gabrecht, T, Michetti, P, Schreiber, S, Ortner, M-A
JournalEndoscopy
Volume43
Issue7
Pagination604-16
Date Published2011 Jul
DOI10.1055/s-0030-1256382
ISSN1438-8812
Mots-clésAminolevulinic Acid, Animals, Apoptosis, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes, Colitis, Colonoscopy, Cytokines, Disease Models, Animal, Dose-Response Relationship, Drug, Mice, Mice, Inbred BALB C, Photochemotherapy, Photosensitizing Agents, Polymerase Chain Reaction, T-Lymphocytes
Abstract

BACKGROUND AND STUDY AIMS: Low dose photodynamic therapy (LDPDT) may modify the mucosal immune response and may thus provide a therapy for Crohn's disease. We evaluated the efficacy and safety of this technique in a murine T cell-mediated colitis model.

METHODS: The safety of LDPDT was first tested in BALB/c mice. Naïve T cells were used to induce colitis in mice with severe combined immunodeficiency, which were followed up endoscopically, and a murine endoscopic index of colitis (MEIC) was developed. The efficacy of LDPDT (10 J/cm (2); delta-aminolevulinic acid, 15 mg/kg bodyweight) was then tested on mice with moderate colitis, while a disease control group received no treatment. The MEIC, weight, length, and histology of the colon, cytokine expression indices, number of mucosal CD4 (+) T cells, percentage of apoptotic CD4 (+) T cells, body weight, and systemic side effects were evaluated.

RESULTS: LDPDT improved the MEIC ( P = 0.011) and the histological score ( P = 0.025), diminished the expression indices of the proinflammatory cytokines, interleukin-6 ( P = 0.042), interleukin-17 ( P = 0.029), and interferon-gamma ( P = 0.014), decreased the number of mucosal CD4 (+) T cells, and increased the percentage of apoptotic CD4 (+) T cells compared with the disease control group. No local or systemic side effects occurred.

CONCLUSION: LDPDT improves murine T cell-mediated colitis, decreases the proinflammatory cytokines interleukin-6, interleukin-17, and interferon-gamma, and decreases the number of CD4 (+) T cells. No adverse events were observed. Therefore, this technique is now being evaluated in patients with inflammatory bowel disease.

Alternate URL

http://www.ncbi.nlm.nih.gov/pubmed/21623559?dopt=Abstract

Alternate JournalEndoscopy
Citation Key / SERVAL ID3058
PubMed ID21623559

                         

IUMSP | www.iumsp.ch
Institut universitaire de médecine sociale et préventive
Route de la Corniche 10, 1010 Lausanne - Switzerland
+41 21 314 72 72 | dess.info@unisante.ch

Go to top